Furthermore, a real-world study revealed that patients treated with PD-1/PD-L1 inhibitors showed better control of intracranial disease and experienced a reduced rate of intracranial progression in comparison to ES-SCLC patients who received only chemotherapy (36). The gene discussed is PDCD1; the disease is small cell lung carcinoma.